Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells

Journal of Nuclear Medicine

Volumn 48, Issue 9, 2007, Pages 1553-1561

  Kwang, Il Kim ^a   Joo, Hyun Kang ^a   Chung, June Key ^a,b   Yong, Jin Lee ^a   Jae, Min Jeong ^a   Dong, Soo Lee ^a   Myung, Chul Lee ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Anaplastic thyroid cancer; Doxorubicin; Gene therapy; Imaging reporter gene; Transgene

Indexed keywords

ADENOVIRUS VECTOR; DOXORUBICIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IODIDE; LUCIFERASE; MESSENGER RNA; PERTECHNETIC ACID TC 99M; PLASMID VECTOR; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER ADJUVANT THERAPY; CANCER MODEL; CONTROLLED STUDY; CYTOMEGALOVIRUS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; THYROID CARCINOMA; TRANSGENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; DOXORUBICIN; GENE THERAPY; HUMANS; I-KAPPA B PROTEINS; IODINE RADIOISOTOPES; MALE; MICE; MICE, NUDE; PROMOTER REGIONS (GENETICS); RADIOTHERAPY, ADJUVANT; SYMPORTERS; THYROID NEOPLASMS; TRANSFECTION; TRANSGENES;

EID: 34548572068     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.038612     Document Type: Article

References (37)

1. Fischer U, Steffens S, Frank S, Rainov NG, Schulze-Osthoff K, Kramm CM. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5- fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005;24:1231-1243.
2. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 1997;4:113-117.
3. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006;13:975-992.
4. Buchsbaum DJ, Chaudhuri TR, Zinn KR. Radiotargeted gene therapy. J Nucl Med. 2005;46(suppl 1):179S-186S.
5. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526-6530.
6. Haberkorn U, Henze M, Altmann A, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med. 2001;42:317-325.
7. Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther. 2002;2:393-402.
8. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium Iodide symporter. Biochem Biophys Res Commun. 1996;226:339-345.
9. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188-1200.
10. Smit JW, Shroder-van der Elst JP, Karperien M, et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid. 2000;10:939-943.
11. Lee YJ, Chung JK, Shin JH, et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid. 2004;14:889-895.
12. Vereecque R, Saudemont A, Wickham TJ, et al. Gamma-irradiation enhances transgene expression in leukemic cells. Gene Ther. 2003;10:227-233.
13. Das KC, White CW. Activation of NF-κB by antineoplastic agents: role of protein kinase C. J Biol Chem. 1997;272:14914-14920.
14. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-κ B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989;8:4251-4258.
15. Kim KI, Chung JK, Kang JH, et al. Visualization of endogenous p53-mediated transcription in vivo using sodium iodide symporter. Clin Cancer Res. 2005;11:123-128.
16. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med. 2006;47:854-862.
17. - symporter gene. Endocrinology. 1997;138:4493-4496.
18. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661-668.
19. Min JJ, Chung JK, Lee YJ, et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter. Nucl Med Biol. 2002;29:537-545.
20. Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res. 2003;63:1333-1338.
21. DeMatteo RP, Yeh H, Friscia M, et al. Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases. Ann Surg Oncol. 1999;6:88-94.
22. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther. 1997;8:2019-2029.
23. Nicklin SA, Wu E, Nemerow GR, Baker AH. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther. 2005;12:384-393.
24. Mastakov MY, Baer K, Xu R, Fitzsimons H, During MJ. Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol Ther. 2001;3:225-232.
25. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA. 2006;103:17684-17689.
26. Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer. 1991;27:532-535.
27. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466-468.
28. Bregman DB, Pestell RG, Kidd VJ. Cell cycle regulation and RNA polymerase II. Front Biosci. 2000;5:D244-D257.
29. O'Loughlin C, Heenan M, Coyle S, Clynes M. Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur J Cancer. 2000;36:1149-1160.
30. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of 1 kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267:1485-1488.
31. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663.
32. Magne N, Toillon RA, Bottero V, et al. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 2006;231:158-168.
33. Habraken Y, Piette J. NF-kappaB activation by double-strand breaks. Biochem Pharmacol. 2006;72:1132-1141.
34. Wade FJ, Klucher KM, Spector DH. An AP-1 binding site is the predominant cis-acting regulatory element in the 1.2-kilobase early RNA promoter of human cytomegalovirus. J Virol. 1992;66:2407-2417.
35. Rideg K, Hirka G, Prakash K, et al. DNA-binding proteins that interact with the 19-base pair (CRE-like) element from the HCMV major immediate early promoter in differentiating human embryonal carcinoma cells. Differentiation. 1994;56:119-129.
36. Ghazal P, DeMattei C, Giulietti E, Kliewer SA, Umesono K, Evans RM. Retinoic acid receptors initiate induction of the cytomegalovirus enhancer in embryonal cells. Proc Natl Acad Sci USA. 1992;89:7630-7634.
37. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol. 1998;72:180-190.